Medtronic Recalls Guidewires Due to Coating Delamination


November 18, 2013
November 18, 2013 — The U.S. Food and Drug Administration (FDA) has classified the Medtronic’s recently initiated voluntary recall of certain interventional guidewires as a Class I recall.
Based on an internal investigation following a limited number of complaints, including one patient injury, Medtronic began notifying hospitals and distributors worldwide the week of Oct. 21 that the coating on the surfaces of some models of its guidewires from recent lots have the potential to delaminate and detach. The notification requested that all potentially affected units be quarantined immediately and returned to the company as soon as possible for credit and replacement.
Medtronic said it has also taken the necessary steps to prevent future shipments of the recalled products and notified regulatory agencies around the world as appropriate.
The FDA defines a Class I recall as a situation in which there is a reasonable probability that use of, or exposure to, a violative product will cause serious adverse health consequences or death.
The guidewires covered by this recall are designed to facilitate percutaneous coronary interventions (PCI) or the placement of left ventricular leads for cardiac rhythm devices. They include specific lots from the following eight product lines that were manufactured after mid-April 2013:
  • Cougar nitinol workhorse guidewire
  • Cougar steerable guidewire
  • Zinger stainless steel workhorse guidewire
  • Zinger steerable guidewire
  • Thunder extra-support guidewire
  • Thunder steerable guidewire
  • ProVia crossing guidewire
  • Attain Hybrid guide wire
Additional information about the recall, including the lot numbers of affected product, is available on the Medtronic website.
Observations and consequences of the coating issue related to these guidewires should be reported to Medtronic in the United States by calling (877) 526-7890 on weekdays from 8 a.m. to 5 p.m. U.S. Central Time.
Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA.
For more information:,